Why Farbe Firma is the Top Manufacturer of Meropenem for Injection
- Maulik Sudani
- 3 days ago
- 10 min read
Last Updated: July 5, 2026
TL;DR: Meropenem for Injection - a sterile powder for reconstitution containing meropenem (as meropenem trihydrate, buffered with sodium carbonate), the broad-spectrum carbapenem beta-lactam antibiotic that binds the penicillin-binding proteins of the bacterial cell wall and inhibits peptidoglycan synthesis, highly stable to most beta-lactamases including extended-spectrum beta-lactamases (ESBLs) and AmpC and active against Gram-positive and Gram-negative aerobes and anaerobes including Pseudomonas aeruginosa and the Enterobacterales, supplied commonly as 500 mg and 1 g vials (expressed as meropenem base) reconstituted with water for injection or an infusion fluid for intravenous injection or infusion - is the carbapenem clinicians rely on for serious hospital infections such as nosocomial pneumonia, complicated intra-abdominal and urinary-tract infections, septicaemia, febrile neutropenia and bacterial meningitis. Because a potency-critical, moisture-sensitive beta-lactam powder is reconstituted and infused into a vein, each vial must deliver a sterile, correctly potent, low-moisture powder that reconstitutes to a clear solution, with the meropenem assay and related substances (including the ring-opened hydrolysis product and any dimer), water content by Karl Fischer, reconstitution time and clarity, particulate and endotoxin, aseptic-process sterility assurance and verified container-closure integrity all mattering to potency and safety. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Meropenem for Injection at our Gujarat, India facility and supplies it to intensive-care, infectious-disease, surgical and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Carbapenem antibiotic (beta-lactam) - meropenem binds the penicillin-binding proteins of the bacterial cell wall and blocks peptidoglycan cross-linking so the wall fails and the organism dies, it is highly stable to most beta-lactamases including extended-spectrum beta-lactamases (ESBLs) and AmpC and, unlike imipenem, is stable to human renal dehydropeptidase-I so it needs no cilastatin, and Meropenem for Injection (a sterile powder reconstituted to 500 mg or 1 g for intravenous injection or infusion) demands a correctly potent, low-moisture, sterile powder in every vial.
Certified manufacturing: WHO-GMP certified plant, dedicated beta-lactam ISO Class 5 aseptic core with segregated air handling, validated water-for-injection loops, dedicated aseptic dry-powder compounding and vial filling with cross-contamination controls, control of the meropenem assay and related substances (including the ring-opened hydrolysis product and dimer) by HPLC, water content by Karl Fischer, reconstitution time and solution clarity, particulate and endotoxin, media-fill-validated aseptic-process sterility assurance, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, media-fill and aseptic-process-validation data, sterilisation and container-closure data, forced-degradation data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile carbapenem-antibiotic powder-for-injection contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets with reconstitution and infusion instructions, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Meropenem for Injection Demands a Premium Manufacturer
Meropenem for Injection is a mainstay of serious hospital anti-infective therapy across many markets. It is the carbapenem a clinician reaches for when an infection is severe, mixed or resistant and empirical treatment cannot be allowed to fail - in nosocomial and ventilator-associated pneumonia, complicated intra-abdominal infection, complicated urinary-tract infection and pyelonephritis, septicaemia, febrile neutropenia in the immunocompromised, and bacterial meningitis, where meropenem's penetration into the cerebrospinal fluid is valued. Meropenem is one of the broadest-spectrum beta-lactams available: it binds the penicillin-binding proteins of the bacterial cell wall and halts peptidoglycan cross-linking, it is highly stable to most beta-lactamases including the extended-spectrum beta-lactamases and AmpC enzymes that defeat cephalosporins, and it covers Gram-positive and Gram-negative aerobes and anaerobes, including Pseudomonas aeruginosa and the Enterobacterales. Unlike imipenem it is stable to human renal dehydropeptidase-I and so does not require co-administration with cilastatin. What makes the parenteral form distinctive is that it delivers dependable, broad-spectrum, bactericidal cover in some of the sickest patients in the hospital, so the prescriber depends on a vial whose potency and sterility are beyond doubt.
That clinical reality places real demands on the manufacturer. Meropenem for Injection is presented not as a ready-to-use solution but as a sterile powder for reconstitution, because meropenem is a moisture-sensitive beta-lactam whose ring hydrolyses in aqueous solution - it is supplied dry as meropenem trihydrate buffered with sodium carbonate, and reconstituted with water for injection for a slow intravenous bolus or diluted in an infusion fluid for infusion immediately before use, effervescing gently as the carbonate releases carbon dioxide. Its strength is expressed as meropenem base, most commonly a 500 mg or 1 g vial, with 250 mg presentations in some markets. As a beta-lactam antibiotic, potency is the defining attribute: the assay must confirm the labelled milligrams of meropenem base, and the related-substance methods must detect the ring-opened hydrolysis product and the meropenem dimer, all by validated HPLC, because an under-strength carbapenem risks treatment failure and the selection of resistant organisms in exactly the patients who can least afford it. The powder must be low in moisture, verified by Karl Fischer titration, because residual water accelerates hydrolysis of the beta-lactam ring; reconstitution must give a clear, colourless to pale-yellow solution within a defined time. Because a dry, heat-labile beta-lactam cannot be terminally sterilised, sterility is achieved by aseptic processing - sterilising-grade filtration of any solution step followed by aseptic filling under ISO Class 5 in dedicated, segregated beta-lactam suites, validated by media fills - with endotoxin held very low and container-closure integrity assured for the sealed vial. Choosing a Meropenem for Injection manufacturer that treats assay and related-substance control, moisture control and dedicated-facility aseptic sterility assurance as core disciplines is what protects the patient at the point of care.
What Sets a World-Class Meropenem for Injection Manufacturer Apart
A world-class manufacturer of Meropenem for Injection invests in three areas that weaker suppliers underfund: precise, validated control of the meropenem assay and related substances by HPLC - confirming the labelled potency in milligrams of base and detecting the ring-opened hydrolysis product and the dimer a moisture-sensitive beta-lactam can form; rigorous dedicated-facility and cross-contamination control, because a beta-lactam antibiotic must be manufactured in segregated suites with their own air handling to prevent the trace cross-contamination and sensitisation that regulators treat as a critical risk; and tender-ready dossier support, including the aseptic-process-validation, moisture and stability data, for a carbapenem procured through intensive-care, infectious-disease and ministry-of-health channels. It starts with the raw materials - pharmacopoeial meropenem trihydrate of controlled potency, water content and impurity profile, and sodium carbonate of the right grade - each sourced from qualified, audited suppliers with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the value of the product is a precise, stable, fully potent, sterile dose of a broad-spectrum carbapenem, the assay, the related substances, the endotoxin and the sterility assurance are treated as central evidence rather than supporting annexes.
Compounding and filling then have to build - and defend - a correctly potent, low-moisture, sterile powder. Because meropenem hydrolyses in water, there is no wet hold: the sterile meropenem trihydrate is blended with sterile sodium carbonate and handled as a dry powder throughout, or any solution step is sterilising-grade filtered and processed quickly and cold. The powder is filled into glass vials under ISO Class 5 conditions in a low-humidity, dedicated beta-lactam suite with segregated air handling that protects both the moisture specification and the wider facility, and the vials are stoppered and sealed under aseptic conditions validated by regular media fills, because a heat-labile beta-lactam cannot be terminally sterilised. Filled units are 100 % inspected for fill, closure and any particulate or cosmetic defect; in-process and release testing confirm the meropenem assay and the delivered milligrams of base, the related-substance profile including the ring-opened product and dimer by HPLC, water content by Karl Fischer, the reconstitution time and clarity of the reconstituted solution, its pH and colour, visible and sub-visible particulate matter, uniformity of the filled mass, and that endotoxin is held well within limits so the reconstituted solution is safe for intravenous use. Because the product is a potency-critical, aseptically filled, moisture-sensitive beta-lactam, the assay, the related substances and the moisture are confirmed on the finished vial, so the powder that leaves the plant reconstitutes to the same fully potent, clear, in-specification solution the specification requires - with no loss of potency and no out-of-limit degradation in the vial across shelf life.
Quality Systems Behind Every Meropenem for Injection
Every Farbe Firma Meropenem for Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of meropenem against reference standards with confirmation of the delivered milligrams of base, control of related substances including the ring-opened hydrolysis product and the dimer, water content by Karl Fischer, the reconstitution time and clarity of the reconstituted solution, its pH and colour, uniformity of the filled mass, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the sealed vial. Certificates of analysis are issued with full traceability back to each meropenem lot, the primary-packaging lot and the qualified person responsible for release. Because the product is an aseptically filled, moisture- and heat-sensitive carbapenem whose clinical value depends on delivered potency, the assay, the related substances and the moisture are qualified across the process so the powder's stability is demonstrated rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, dedicated and segregated beta-lactam suites, validated aseptic dry-powder filling with routine media fills, sterilising-grade filtration with filter-integrity testing, low-humidity powder handling with cleaning validation and cross-contamination controls, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a broad-spectrum carbapenem given to the sickest patients must deliver its full labelled potency to clear the infection and to limit the selection of resistant organisms, we treat the assay, the related substances, the moisture, the endotoxin and the fill uniformity as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions, with the assay, related substances and moisture followed across the study, so the powder stays in specification across the labelled shelf life and the reconstitution and storage instructions on the label are supported by real data.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Meropenem for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad antibiotic, anti-infective and critical-care portfolio. For Meropenem for Injection specifically, we supply the carbapenem antibiotic as a sterile powder for reconstitution in 500 mg and 1 g vials expressed as meropenem base, together with other strengths, under WHO-GMP conditions, with country-specific strengths, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the assay, related-substance, aseptic-process-validation, moisture and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Meropenem for Injection can request the assay, related-substance and accelerated-stability summaries up front, which is often the deciding technical evidence for a carbapenem in hospital-formulary and ministry-of-health review, since it is the confirmed potency of a fully active antibiotic and a validated aseptic sterility assurance that separate a dependable meropenem from an unreliable one.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, media-fill and aseptic-process-validation reports, moisture and container-closure reports, forced-degradation packages, and translated package inserts and artwork - including the reconstitution and slow-intravenous or infusion instructions, the note that meropenem needs no cilastatin, and the use-reconstituted-solution-promptly storage caution - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Meropenem for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the dedicated beta-lactam aseptic dry-powder compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through meropenem sourcing and impurity control, the stability of the beta-lactam ring and the control of the ring-opened hydrolysis product and dimer, moisture control by Karl Fischer, the sodium-carbonate-buffered formulation and its effervescent reconstitution, the assay and related-substance strategy by HPLC, aseptic-process validation and media fills, dedicated-facility segregation and cross-contamination controls for beta-lactam manufacture, reconstitution behaviour and solution clarity, endotoxin control, container-closure integrity and shelf-life choices in real detail. For a carbapenem where assay accuracy, sterility and stability directly govern potency and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Meropenem for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Meropenem for Injection at a Gujarat, India facility with a dedicated beta-lactam ISO Class 5 aseptic area and segregated air handling, validated water-for-injection systems, dedicated aseptic dry-powder compounding and vial filling with cross-contamination controls, sterilising-grade filtration, media-fill-validated aseptic filling, 100 % inspection and continuous environmental monitoring.
Which strengths and presentations of Meropenem for Injection do you supply?
Our carbapenem antibiotic is available as a sterile powder for reconstitution containing meropenem (as meropenem trihydrate buffered with sodium carbonate), commonly as 500 mg and 1 g vials expressed as meropenem base, with 250 mg presentations available where required. It is reconstituted with water for injection for a slow intravenous bolus or with an infusion fluid for intravenous infusion. Custom strengths, fill formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Meropenem for Injection mainly used for?
Meropenem for Injection is used to treat serious infections such as nosocomial and ventilator-associated pneumonia, complicated intra-abdominal and urinary-tract infections, septicaemia, febrile neutropenia and bacterial meningitis. It is a broad-spectrum carbapenem that binds the penicillin-binding proteins of the bacterial cell wall, is highly stable to most beta-lactamases including ESBLs, and is active against Gram-positive and Gram-negative aerobes and anaerobes including Pseudomonas aeruginosa and the Enterobacterales; unlike imipenem it needs no cilastatin. It is given intravenously. Farbe Firma verifies the assay, related substances, water content, reconstitution and endotoxin at release so each vial delivers a fully potent, sterile powder.
Can Farbe Firma support country-specific registrations for Meropenem for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, media-fill and aseptic-process-validation data, related-substance and forced-degradation packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Meropenem for Injection contract manufacturing?
MOQs vary by strength, fill format, label complexity and dossier requirements. For our sterile powder-for-injection vial presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments